投资快报 3

葉芬

回复  葉芬


    ANX和SSN还没卖不敢买进...但会继续观察..价钱已很吸引了...
SUNNY仔 发表于 5-1-2011 05:02 PM

SSN 漲勢還很強。
要是能再加上好消息，股價2元沒問題。

migo

回复 2322# 葉芬


    注意ARNA 来势凶凶
          CHGS迟来的鸟没虫吃

葉芬

PZG
SSN


PZG 只是調整2天而已。

SUNNY仔

回复 2323# migo

买来玩玩的420UNIT ARNA出货了..赚了五十多蚊美元买汉宝包吃...

SUNNY仔

回复 2324# 葉芬


    开市时金价掉,还以为PZG会继续探低的...结果却是反弹...

roberto

回复 2325# SUNNY仔

你的汉堡相当贵一下....

roberto

press release
Jan. 5, 2011, 7:00 p.m. EST
Samson Oil & Gas Updates Operations & Comments on Market Activity

DENVER, Jan05, 2011 (BUSINESS WIRE) -- Samson Oil & Gas Limited SSN 1.56, -0.02, -1.27%) advises on recent operational activity:

NORTH PLATTE3-D SEISMIC SURVEY

Acquisition operations have been completed in the North Platte 3-D seismic project. This acquisition encompassed 60.4 square miles and will assist the appraisal of the area by the identification of naturally occurring fractures in the Cretaceous Niobrara Formation and conventional structural/stratigraphic targets that are productive in the area.

The acquisition operations went smoothly with some minor downtime experienced because of high velocity winds, which would have caused ambient noise levels to be exceeded during recording.
The data has been progressively loaded into a Denver-based seismic processing house and the first products from this processing are expected to be available to Samson by mid January.

NORTH STOCKYARD OILFIELD

The fracture stimulation operations for the Earl and Rodney wells that were expected to be performed in December are now expected to be concluded during the first quarter of 2011. This delay is unfortunate and has been caused by the heightened level of activity in the Williston Basin.
Samson is planning to enter into a long-term contract for the provision of both drilling and fracture stimulation services so that these delays are not replicated in its Goshen County project.

RECENT MARKET ACTIVITY

Samson also provides advice concerning the recent increase in trading volumes and prices of Samson's ordinary shares, which are traded on the Australian Stock Exchange, and its American Depositary Shares, representing twenty ordinary shares, which trade in the U.S. on NYSE Amex.
"Samson is not aware of any recent corporate developments to account or this activity," said Samson's Managing Director Terry Barr, "We are aware, however, that an oil and gas consulting company engaged by Samson to provide investor relations and other services, did publish a report on Samson dated December 29, 2010, which was an update of its prior report on the company.Though Samson cannot comment on the accuracy of that estimate or any of the other information in the report, we are also aware that the new report estimated Samson's net asset value per share to be significantly greater than current market prices for its shares,"

The report also discusses the considerable activity being undertaken by Samson's competitors in the Denver-Julesburg Basin with respect to the development of the Niobrara Formation, including credible initial production rates, and comments on the prospects for this play becoming an important oil producing unit.

While Samson did not participate in the preparation or publication of the report and is not responsible for the accuracy or quality of any the statements, information or conclusions contained therein, a copy of the report has been posted on Samson's website, www.samsonoilandgas.com ,for the convenience of Samson's shareholders and other interested parties.

葉芬

回复  葉芬


    开市时金价掉,还以为PZG会继续探低的...结果却是反弹...
SUNNY仔 发表于 6-1-2011 08:16 AM

    所以說股市是不能預測的，特別是美股市。

葉芬

回复  SUNNY仔

你的汉堡相当贵一下....
roberto 发表于 6-1-2011 08:21 AM

美金的漢堡包當然是貴些的。
但 美味可口。

葉芬

press release
Jan. 5, 2011, 7:00 p.m. EST
Samson Oil & Gas Updates Operations & Comments on Market ...
roberto 发表于 6-1-2011 08:24 AM

AUS-SSN 看了這新聞，股價跌了0.003 （-4.05%）

After Hours SSN-US 跌了8%，不過只有5000Shares 交易。還好。還好。


又給你說中，SSN不出新聞還好過出新聞。

migo

回复 2325# SUNNY仔


    恭喜呀!什么汗宝这么贵!我吗最近很忙.没时间玩投机!今天买了HDY7500 UNIT.
   看看能赚点小钱!看来ARNA还是有希望的.

葉芬

回复  SUNNY仔


    恭喜呀!什么汗宝这么贵!我吗最近很忙.没时间玩投机!今天买了HDY7500 UNIT.
   看 ...
migo 发表于 6-1-2011 10:16 AM

    前天我有貼上來說 HDY又要來了。

葉芬

AUS - SSN


0.074 0.000 (0.00%)
Jan 6 - Close
ASX data delayed by 20 mins

澳洲的SSN平盤。
就看今晚美國的SSN表演了。

nigege

sprint nextel 的vol也算高吗？？有潜能吗？

SUNNY仔

回复 2327# roberto


    昨晚去探望以为前辈,她刚从英国回来,说英国的MC一套要价27块英镑 ,至于美国的,加水钱精神精力的,差不多啦..

nigege

sprint nextel 的vol也算高吗？？有潜能吗？

SUNNY仔

回复 2334# 葉芬


    SSN-US PRE-MART掉了...起码调整5%...

SUNNY仔

ANX PRE-MART 狂起接近30%...
芬姐米哥,有什么意见?卖还是等$4...

SUNNY仔

结果在排着$3.55...因为记起芬姐的签名...看可否套利先...哈哈

葉芬

ANX PRE-MART 狂起接近30%...
芬姐米哥,有什么意见?卖还是等$4...
SUNNY仔 发表于 6-1-2011 10:25 PM

有很大的機會拿到FDA的Approval哦。。要我是我會賣出部份，留一些等FDA-Approval。


FDA Accepts Exelbine(TM) NDA for Filing

Thu Jan 06 08:00:00 2011 EST
SAN DIEGO, Jan. 6, 2011 /PRNewswire via COMTEX News Network/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S.
Food and Drug Administration (FDA) has accepted for filing the New Drug Application
(NDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.
The filing of the Exelbine NDA means the FDA has made a threshold determination
that it is sufficiently complete to permit a substantive review.
"We are pleased to have reached this important milestone, and look forward
to working with the FDA on moving Exelbine toward approval in 2011," said Brian
M. Culley, Chief Executive Officer of ADVENTRX.
About Exelbine
ADVENTRX is seeking approval of Exelbine for the same indications as Navelbine(R),
a branded formulation of vinorelbine, including non-small cell lung cancer. ADVENTRX
submitted the NDA as a 505(b)(2) application that relies in part on the FDA's findings
of safety and effectiveness of a reference drug. The Exelbine NDA includes data
from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence
of Exelbine and Navelbine, the reference drug. In this clinical bioequivalence study,
Exelbine and the reference drug were determined by ADVENTRX to be bioequivalent.
ADVENTRX retains exclusive worldwide rights to Exelbine, other than in South
Korea, China, Hong Kong, Macau and Taiwan. In March 2010, the FDA conditionally
accepted "Exelbine" as the proposed proprietary name for ANX-530. The United
States Patent and Trademark Office has allowed patent claims related to Exelbine,
which claims will issue in January 2011 and expire in November 2027.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product
candidates are being developed to improve the performance of existing anti-cancer
drugs by addressing limitations associated principally with their safety and use.
More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements that are
based on ADVENTRX's current expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements regarding regulatory approval of Exelbine
based on the 505(b)(2) NDA accepted for filing, working with the FDA in the regulatory
review process and the bioequivalence of Exelbine and Navelbine. Actual events or
results may differ materially from those expressed or implied by the forward-looking
statements in this press release due to a number of risks and uncertainties, including,
without limitation: the risk that ADVENTRX does not receive FDA approval of Exelbine
on a timely basis, or at all; the potential for the FDA to determine that the bioequivalence
data and other information included in the Exelbine NDA does not adequately support
bioequivalence with Navelbine, including as a result of performing pharmacokinetic
equivalence analyses based on a patient population other than the population on
which ADVENTRX based its analysis; the potential that changes made in transferring
the manufacturing process for Exelbine may result in a lack of comparability between
the commercial product and the material used in the bioequivalence trial; the risk
that results of future stability testing on samples of Exelbine do not support comparability
between ADVENTRX's prior and intended commercial manufacturing sites or a commercially-viable
expiration dating period; the potential for the FDA to impose other requirements
to be completed before or after approval of the Exelbine NDA, including that the
FDA may require ADVENTRX to perform additional nonclinical, bioequivalence or clinical
studies; ADVENTRX's reliance on third parties to assist with its bioequivalence
trials, regulatory submissions, manufacturing and other important aspects of the
Exelbine development program, and the risk that FDA approval may be delayed if their
performance is found to have been substandard; the risk that any patent issued to
ADVENTRX may not provide sufficient protection and market exclusivity for Exelbine
and may be challenged, invalidated, infringed or circumvented by third parties,
including by ADVENTRX's competitors; ADVENTRX's dependence on the success of Exelbine
as its first product candidate to be submitted for regulatory approval; the potential
that ADVENTRX may require substantial additional funding in order to obtain FDA
approval for and commercialize Exelbine, and the risk that ADVENTRX may not be able
to raise sufficient capital when needed, or at all; the potential for ADVENTRX to
enter into a commercial partnership or other strategic transaction relating to Exelbine
and that such partnership or transaction may not succeed in commercializing Exelbine;
and other risks and uncertainties more fully described in ADVENTRX's press releases
and periodic filings with the Securities and Exchange Commission. ADVENTRX's public
filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements,
which speak only as of the date when made. ADVENTRX does not intend to revise or
update any forward-looking statement set forth in this press release to reflect
events or circumstances arising after the date hereof, except as may be required
by law.
SOURCE  ADVENTRX Pharmaceuticals, Inc.